ENTRY       D00168                      Drug
NAME        Cytarabine (JP18/USP/INN);
            ARA-C;
            Depocyt (TN)
PRODUCT
  GENERIC   CYTARABINE (Fresenius Kabi USA)
            CYTARABINE (Gland Pharma Limited)
            CYTARABINE (Gland Pharma Limited)
            CYTARABINE (Hospira)
            CYTARABINE (Hospira)
            CYTARABINE (Hospira)
            CYTARABINE (Hospira)
            CYTARABINE (Meitheal Pharmaceuticals)
            CYTARABINE (Meitheal Pharmaceuticals)
            CYTARABINE (Meitheal Pharmaceuticals)
            CYTARABINE (Meitheal Pharmaceuticals)
            CYTARABINE (Sagent Pharmaceuticals)
            CYTARABINE (Sagent Pharmaceuticals)
FORMULA     C9H13N3O5
EXACT_MASS  243.0855
MOL_WEIGHT  243.2166
CLASS       Antineoplastic
             DG02018  Antimetabolite
              DG01958  Nucleic acid derivative, antineoplastic
               DG01439  Arabinofuranosyl type antineoplastic
REMARK      Same as: C02961
            Therapeutic category: 4224
            ATC code: L01BC01
            Chemical structure group: DG00686
            Product (DG00686): D00168<JP/US> D03046<JP>
EFFICACY    Antineoplastic, Antimetabolite, DNA polymerase inhibitor
  DISEASE   Lymphomatous meningitis [DS:H01668]
            Acute myeloid leukemia [DS:H00003]
            Chronic myelocytic leukemia [DS:H00004]
COMMENT     Active metabolite: Cytarabine-5;-triphosphate (ara-CTP)
TARGET      DNA polymerase
INTERACTION  
STR_MAP     map07041  Antineoplastics - antimetabolic agents
            map07046  Immunosuppressive agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01B ANTIMETABOLITES
                L01BC Pyrimidine analogues
                 L01BC01 Cytarabine
                  D00168  Cytarabine (JP18/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antimetabolites
               Cytarabine
                D00168  Cytarabine (JP18/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               422  Antimetabolites
                4224  Cytosines
                 D00168  Cytarabine (JP18/USP/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02018  Antimetabolite
               DG01958  Nucleic acid derivative, antineoplastic
                DG01439  Arabinofuranosyl type antineoplastic
                 DG00686  Cytarabine
                  D00168  Cytarabine
            Drug classes [BR:br08332]
             Antineoplastic
              DG02018  Antimetabolite
               D00168  Cytarabine
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00168  Cytarabine
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00168
            Prodrugs [br08324.html]
             D00168
            Drug groups [BR:br08330]
             Antineoplastic
              DG02018  Antimetabolite
               DG01958  Nucleic acid derivative, antineoplastic
                DG01439  Arabinofuranosyl type antineoplastic
                 DG00686  Cytarabine
DBLINKS     CAS: 147-94-4
            PubChem: 7847236
            ChEBI: 28680
            PDB-CCD: AR3
            LigandBox: D00168
            NIKKAJI: J2.958K
ATOM        17
            1   C1y C    22.3986  -17.4645
            2   N4y N    23.7916  -16.8812
            3   O2x O    21.2637  -16.6396
            4   C1y C    21.9658  -18.7927
            5   C8y C    25.0030  -17.5661
            6   C8x C    23.7682  -15.4827
            7   C1y C    20.1286  -17.4645
            8   C1y C    20.5616  -18.7927
            9   O1a O    22.7848  -19.9278
            10  N5x N    26.2080  -16.8485
            11  O5x O    25.0208  -18.9659
            12  C8x C    24.9731  -14.7651
            13  C1b C    18.7947  -17.0317
            14  O1a O    19.7425  -19.9278
            15  C8y C    26.1901  -15.4486
            16  O1a O    17.7591  -17.9735
            17  N1a N    27.3966  -14.7369
BOND        18
            1     1   2 1 #Up
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 1
            6     3   7 1
            7     4   8 1
            8     4   9 1 #Up
            9     5  10 1
            10    5  11 2
            11    6  12 2
            12    7  13 1 #Up
            13    8  14 1 #Down
            14   10  15 2
            15   13  16 1
            16   15  17 1
            17    7   8 1
            18   12  15 1
///
